DUBLIN, Ireland - Trinity Biotech plc (NASDAQ:TRIB), a leading provider of diagnostic solutions for the healthcare industry, ...

Trinity Biotech's two rapid HIV tests will continue to be funded under PEPFAR, a significant global initiative to combat HIV/AIDS. The company confirmed that other testing programs using their ...

In other recent news, Trinity Biotech has been active on multiple fronts. The company secured continued U.S. government funding for its HIV testing programs, despite a broader review of foreign aid.

Trinity Biotech ( ($TRIB) ) has issued an announcement. Trinity Biotech announced a positive update regarding the U.S. government’s funding for ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...

In other recent news, Trinity Biotech has been active on multiple fronts. The company secured continued U.S. government funding for its HIV testing programs, despite a broader review of foreign aid.

which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity Biotech has received earlier than expected approval from t ...